Nani Research LLC

1. Akebia Therapeutics Inc $842,310 514 payments
2. Retrophin, Inc. $231,378 214 payments
3. AstraZeneca Pharmaceuticals LP $171,472 9 payments
4. Eli Lilly and Company $152,666 3 payments
5. Bayer HealthCare Pharmaceuticals Inc. $143,435 25 payments
6. Hoffmann-La Roche Limited $104,030 23 payments
7. Boehringer Ingelheim Pharmaceuticals, Inc. $79,756 8 payments
8. Novartis Pharmaceuticals Corporation $69,390 2 payments
9. AstraZeneca UK Limited $55,397 1 payment
10. Aurinia Pharma U.S., Inc. $18,250 4 payments

1. Akb-6548-Ci-0014 $216,971 288 payments
2. Akb-6548-Ci-0014 $158,927 8 payments
3. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $152,666 3 payments
4. Akb-6548-Ci-0015 $138,311 175 payments
5. BAY94-8862, Finerenone Phase 3 in non-diabetic CKD $137,729 20 payments
6. Akb-6548-Ci-0015 $117,884 5 payments
7. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Correction) $111,495 19 payments
8. Double blind study to determine efficacy of ASO Factor B in IgAN $104,030 23 payments
9. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Conversion) $98,722 19 payments
10. 021Igan17001 $96,009 131 payments

1. Other $153,475 168 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.